Claims
- 1. A compound of the formula ##STR21## wherein R.sub.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen or halogen, R.sup.3, R.sup.4 and R.sup.5, independently, are hydrogen, alkanoyl, benzoyl or lower alkyl; R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; X is alkylene of 3 to 7 carbon atoms; and n is as an integer of one to four provided one of R.sup.3, R.sup.4 or R.sup.5 is alkanoyl or benzoyl and the other two, independently, are hydrogen or lower alkyl; or
- an enantiomer thereof, or, when R.sup.7 is hydrogen, a salt thereof, with a pharmaceutically acceptable base.
- 2. A compound, in accordance with claim 1, wherein R.sup.1 is lower alkyl, R.sup.2 is hydrogen, R.sup.3 is alkanoyl or benzoyl, and R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen.
- 3. A compound, in accordance with claim 2, wherein X is alkylene of 3 to 5 carbon atoms.
- 4. A compound, in accordance with claim 3, wherein R.sup.3 is acetyl.
- 5. A compound, in accordance with claim 4, wherein R.sup.1 is propyl.
- 6. A compound, in accordance with claim 1, racemic-6-acetyl-7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy3,4-dihydro]-2-methyl-8-n-propyl-2H-1-benzopyran-2-propanoic acid.
- 7. A compound, in accordance with claim 1, racemic-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy]-3,4-dihydro-2H-1-benzopyran-2-pentanoic acid.
- 8. A pharmaceutical composition having SRS-A antagonistic activity, comprising an effective amount of a compound of the formula ##STR22## wherein R.sub.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen or halogen; R.sup.3, R.sup.4 and R.sup.5, independently, are hydrogen, alkanoyl, benzoyl or lower alkyl; R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; X is alkylene of 3 to 7 carbon atoms; and n is an integer of one to four; provided that one of R.sup.3, R.sup.4 or R.sup.5 is alkanoyl or benzoyl and the other two, independently, are hydrogen or lower alkyl; or
- an enantiomer thereof, or, when R.sup.7 is hydrogen, a salt thereof, with a pharmaceutically acceptable base, and an inert carrier material.
- 9. A composition in accordance with claim 8, wherein the compound of formula I is racemic-6-acetyl-7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3,4-dihydro-2-methyl-8-n-propyl-2H-1-benzopyran-2-propanoic acid.
- 10. A composition in accordance with claim 8, wherein the compound of formula I is racemic-6-acetyl-7-[5-(4-acetyl-hydroxy-2-propylphenoxy)pentyloxy]-3,4-dihydro-2H-1-benzopyran-2-pentanoic acid.
- 11. A method of treating allergic conditions requiring SRS-A antagonistic activity, which comprises administering an effective amount of a compound of the formula ##STR23## wherein R.sub.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen or halogen; R.sup.3, R.sup.4 and R.sup.5, independently, are hydrogen, alkanoyl, benzoyl or lower alkyl; R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; X is alkylene of 3 to 7 carbon atoms; and n is an integer of one to four; provided that one of R.sup.3, R.sup.4 or R.sup.5 is alkanoyl or benzoyl and the other two, independently, are hydrogen or lower alkyl; or
- an enantiomer thereof, or, when R.sup.7 is hydrogen, a salt thereof, with a pharmaceutically acceptable base.
- 12. A method in accordance with claim 11, wherein the compound of formula I is racemic-6-acetyl-7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3,4-dihydro-2-methyl-8-n-propyl-2H-1-benzopyran-2-propanoic acid.
- 13. A method in accordance with claim 11, wherein the compound of formula I is racemic-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy]-3,4-dihydro-2H-1-benzopyran-2-pentanoic acid.
RELATED APPLICATIONS
This application is a continuation-in-part of U.S. patent application Ser. No. 507,383, filed June 24, 1983, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4511685 |
Nissen et al. |
Apr 1985 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
507383 |
Jun 1983 |
|